Loss of STING prevents DNA damage-mediated type I IFN production, which renders tumor cells highly susceptible to OV infection (44), suggesting that STING activity might be a crucial indicator to stratify cancer patients for OV-based therapies. The gene discussed is STING1; the disease is cancer.